Key words: IgA nephropathy; humoral immunity; IgA1 hinge region; proline-rich peptide; O-glycosylation Background. The human IgA1 hinge region is a unique mucin-like O-linked proline-rich glycopeptide, and its core peptide was found to be exposed aberrantly by the underglycosylation in IgA nephropathy (IgAN ). Introduction
Mann-Whitney U-test. A P-value of <0.05 was considered in patients with IgAN by enzyme-linked immunosorbto be a significant difference. ent assay ( ELISA) using a synthetic peptide corresPreliminarily, we examined the specific reactivity of the ponding to the human IgA1 hinge region as an antigen, IgG from patients with IgAN against the sa1HP. The and evaluated the relationship between the underglyco-dose-dependent reactivity of the IgG (serum dilution, sylation of the IgA1 hinge region and the humoral 1/1600-1/100) against the plate-coated sa1HP was immune response. tested using the sera from patients with IgAN (n=6) and controls (n=6) with the above-mentioned method. Each mean±SD of the six cases was expressed, and the statistical difference between IgAN and the control was
Materials and methods
analysed by ANOVA. In addition, the inhibition assays were performed using a free sa1HP and an unrelated 21mer synthetic peptide, human b-endorphin (1-5)+(16-31), Sera were collected from 37 patients (17 males, 20 females, YGGFMTLFKNAIIKNAYKKGE (American Peptide mean age 37 years, range 16-56 years) with biopsy-proven Company, Sunnyvale, CA). Fifty ml of the sera (1/50 dilution) IgAN and 34 control patients (22 males, 12 females, mean from the patients with IgAN (n=6) were added with 50 ml age 43 years, range 17-74 years) with other biopsy-proven of the free synthetic peptides (0-20 mg/ml ) to the sa1HP-renal diseases without glomerular IgA deposition (membrancoated wells. After incubation for 3 h and washing, the IgG ous nephropathy, n=6; non-IgA mesangial proliferative binding to the plate-fixed sa1HP was detected with peroxidglomerulonephritis (GN ), n=4, membranoproliferative GN, ase-conjugated anti-human IgG antibody in the same way. n=4; tubulointerstitial nephritis, n=4; focal glomeruloThe reactivity without inhibitors was regarded as 100%, and sclerosis n=3; lupus nephritis, n=3; lipoid nephrosis, n=2; each mean±SD of the percentage reactivity was expressed. nephrosclerosis, n=2; rapidly progressive GN, n=2; amiloIn order to evaluate the relationship between the underglyidosis, n=2; acute GN, n=1; diabetic nephropathy, n=1).
cosylation of the IgA1 hinge region and the humoral immune A 21mer peptide corresponding to the amino acid response, the reactivity of the IgG from patients with IgAN sequence of the human IgA1 hinge region, against a monoclonal IgA1 which was digested enzymatically PVPSTPPTPSPSTPPTPSPSC, was synthesized by and purto remove the carbohydrates from the IgA1 hinge region chased from Bio-Synthesis, Inc. (Lewisville, TX ). The purity was measured by ELISA. Neuraminidase (NA) from and molecular weight were confirmed by HPLC and MALDIStreptococcus 6646K (1 U/100 ml; Seikagaku Co. Tokyo, TOFMS. The synthetic IgA1 hinge peptide (sa1HP) was Japan), b-galactosidase (GA) from bovine testis (1.0 U/ml; conjugated with bovine serum albumin (BSA, Sigma Sigma Chemical Co.) and a-N-acetylgalactosaminidase Chemical Co., St Louis, MO) for plate coating. The conjuga-(GNA) from Acremonium sp. (13 U/ml; Seikagaku Co.) were tion of BSA with the peptide was performed by the following used in this examination according to the following procedure procedure. A 1.5 ml aliquot of BSA (13.4 mg/ml ) was based on our previous study [15] . The monoclonal IgA1 mixed with 100 ml of N-e-maleimidocaproyloxy succinimide derived from a patient with IgA1-type multiple myeloma (100 mg/ml, Wako Junyaku Co., Tokyo) and incubated for (Funakoshi Co. Tokyo, Japan) was divided into four samples 1 h at room temperature. After desalting, 250 ml of the (1 mg each). The first sample was dissolved in 100 ml of peptide (20 mg/ml ) was added and incubated for 36 h at 0.2 M sodium acetate buffer, pH 5.0 (SAB) without adding 4°C. After desalting, the BSA-conjugated peptide was used any enzymes and was used as a control. The second sample as the antigen for ELISA.
was dissolved in 95 ml of SAB and 5 ml of NA was added to The 96-well microtitration plates (Linbro/Titertek, Flow remove NeuNAc. The third sample was dissolved in 75 ml of General Company, McLean, IL) were coated with 100 ml of SAB and 5 ml of NA and 20 ml of GA were added to remove the BSA-conjugated sa1HP diluted to a concentration of NeuNAc and Gal. The fourth sample was dissolved in 65 ml 10 mg/ml with 0.015 M carbonate buffer, pH 9.6. After of SAB and 5 ml of NA, 20 ml of GA and 10 ml of GNA were blocking of the unreacted sites with 0.01 M phosphate buffer, added to remove NeuNAc, Gal and GalNAc. All the IgA1 pH 7.5, 0.15 M NaCl (PBS ) containing 1% BSA, 100 ml of samples containing the enzymes were incubated overnight at sera (1/100 dilution in PBS ) from patients with IgAN (n= 37°C and then dialysed against PBS. The non-treated, 37) and controls (n=34) were added to the sa1HP-coated NA-treated, NA+GA-treated and NA+GA+GNA-treated and non-coated wells. After incubation for 3 h at room IgA1 were named 'native', 'asialo', 'agalacto' and 'naked' temperature and washing with PBS containing 0.1% BSA IgA1, respectively. The efficacy of the enzymatic treatments and 0.05% Tween-80 (PBS/BSA/Tween), 100 ml of peroxiwas confirmed by binding assays with peanut agglutinin and dase-conjugated goat anti-human IgG (1/500, Fc portionVicia vilosa lectins according to the previously described specific, Organon Teknika Corp., West Chester, PA), antimethod [16 ] . The microtitration plates were coated with human IgA (1/500, a-chain-specific, Organon Teknika Corp.) 100 ml of the IgA1 (10 mg/ml ). After blocking with 1% BSA, and anti-human IgM (1/500, m-chain-specific, Organon 100 ml of the sera (1/100 dilution) from the patients with Teknika Corp.) antibodies were added to the wells. After IgAN (n=6) was reacted against the coated IgA1. Because incubation for 1 h at room temperature and washing with of the non-specificity of NA+GA to O-glycans, we also PBS/BSA/Tween, the plates were exposed to an enzyme performed the same assays using a monoclonal IgA2 substrate consisting of 0.4 mg/ml of o-phenylenediamine (Funakoshi Co., Tokyo, Japan). The IgG reactivity was dihydrochloride (Sigma Chemical Co.) and 0.03% hydrogen detected with peroxidase-conjugated anti-human IgG antiperoxide in a solution containing 0.1 M disodium hydrogen body using the above-mentioned ELISA method. The OD phosphate and 0.05 M citric acid monohydrate. The value in the native IgA1 was regarded as 100% and each developed colour was read at 490 nm with a microplate mean±SD of the percentage reactivity in the deglycosylated reader (Bio-Rad Laboratories, model 450, Richmond, CA).
IgA1 was expressed. Each absorbance level was reduced by that of the nonTo examine the exposure of the IgA1 hinge peptide core sa1HP-coated well. All of the assays were performed in in IgAN, the reactivity of a rabbit polyclonal anti-synthetic triplicate. Each median was expressed. The statistical difference between the two groups was analysed using the IgA1 hinge peptide antibody (anti-sa1HP ab), which was T. Kokubo et al. 30 reported in our previous study [10] , against the serum IgA was measured by ELISA and compared in the IgAN and control groups. The microtitration plates were coated with 100 ml of goat anti-human IgA antibody (10 mg/ml, Fab fraction, Organon Teknika Corp). After blocking with BSA, 100 ml of the sera (1/100 dilution) from the IgAN group (n= 24) and control group (n=24) were added to the wells. After incubation for 3 h at room temperature and washing, 100 ml of the rabbit anti-sa1HP ab (1/100 dilution) was added to the wells. After incubation for 3 h at room temperature and washing, 100 ml of the peroxidase-conjugated goat anti-rabbit IgG antibody (1/500 in PBS, Organon Teknika Corp.) was placed in the wells. After incubation for 1 h at room temperature and washing, the absorbance levels were measured using the above-mentioned method. These assays were performed in triplicate. Each median was expressed. The statistical difference between the two groups was analysed using the Mann-Whitney U test. 
Specific reactivity of serum IgG from IgAN patients against sa1HP
As shown in Figure 1 , the serum IgG from the patients with IgAN reacted against the plate-fixed sa1HP in a dose-dependent manner. The reactivity was significantly higher in the patients with IgAN (n=6) than in the controls (n=6) (ANOVA, P=0.017). In addition, the binding of the IgG from the patients with IgAN (n=6) to the plate-fixed sa1HP was clearly inhibited by the free sa1HP but not by a control peptide (Figure 2 ).
Serum anti-a1HP ab titres in IgAN
As shown in Figure 3 , the serum anti-a1HP ab titres of the IgG and IgM classes were significantly higher in the IgAN group (n=37) than in the control group (n=34) (IgG class, 0.564±0.344 vs 0.331±0.154, P= 0.0014; IgM class, 0.272±0.148 vs 0.141±0.072, P<0.0001). However, the antibody titre of the IgA class was not detectable in all cases of both groups. When more than the mean+2 SDs of the control group was regarded as a positive level of the antia1HP ab titres ( IgG class, >0.639; IgM class, >0.285), the positive rate was 40.5% (15/37) in the IgG class and 43.2% (16/37) in the IgM class in the IgAN group, and 0% (0/34) in both antibody classes in the control group. There is a significant correlation between the Fig. 1 . Serum IgG from patients with IgAN (n=6) reacted against anti-a1HP ab titres of the IgG and IgM classes (R2= sa1HP in a dose-dependent manner. The reactivity was significantly higher in IgAN patients than in controls (n=6).
0.366, P<0.0001). However, no significant correlation
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Reactivity of serum IgG from IgAN patients against deglycosylated IgA1 (monoclonal)
The serum IgG from patients with IgAN (n=6) reacted strongly against the deglycosylated IgA1 compared with native IgA1. When the reactivity against native IgA1 was regarded as 100%, the values were 122±9.5% (mean±SD) against the asialo IgA1, 167±11.5% against the agalacto IgA1 and 188±3.9% against the naked IgA1. The reactivity was increased as the carbohydrates were removed from the IgA1 hinge region, and the reactivity against naked IgA1 was~2-fold higher than that against native IgA1 (Figure 4 ). In addition, there was no significant difference in the reactivity of the patient's IgG against a monoclonal IgA2 between native and deglycosylated IgA2. 
serum IgA in IgAN
As shown in Figure 5 , the reactivity of the rabbit and it was regarded as positive in~40% of the patients polyclonal anti-sa1HP antibody against serum IgA with IgAN. It was also observed that this titre was was significantly higher in the IgAN group (n=24) increased in both the IgG and IgM classes but not than in the control group (n=24) (0.321±0.167 vs detectable in the IgA class, indicating that antibody 0.189±0.137; P=0.0042). There was no significant production against the peptide epitope of the IgA1 correlation between this reactivity and the serum IgA hinge region occurred in the IgG and IgM classes. level.
These observations suggested that these humoral immune responses could result in the formation of IgA1-IgG and IgA1-IgM immune complexes in the Discussion circulation of patients with IgAN. Czerkinsky et al. previously reported that IgA-containing circulating The results of the ELISA using a synthetic peptide immune complexes were found in patients with IgAN corresponding to the human IgA1 hinge region, [17] . The IgA1-IgG and IgA1-IgM interactions medi-PVPSTPPTPSPSTPPTPSPS, as an antigen showed ated by the IgA1 hinge peptide observed in the present that the serum anti-a1HP ab titre was significantly study may be one of the mechanisms involved in the higher in the IgAN group than in the control group, formation of IgA-containing immune complexes in IgAN. Next, we examined the reactivity of serum IgG from the patients with IgAN against native and deglycosylated monoclonal IgA1. This reactivity was found to be greatest in the naked, followed by the agalacto, asialo and native IgA1, in that order; i.e. the more carbohydrates that were removed from the IgA1 hinge region, the greater the reactivity. This result suggests that the accessibility of the anti-a1HP ab to the peptide epitope of the IgA1 hinge region was increased by the enzymatic removal of the carbohydrates from the IgA1 hinge region, and that the carbohydrate moieties including NeuNAc, Gal and GalNAc attached to the hinge region function to protect the peptide epitope. Therefore, if there is some defect in the O-glycans of the IgA1 hinge region, the probability of the peptide epitope being recognized by the anti-a1HP ab expressed on B lymphocytes is thought to increase and, consequently, the B cells will be activated and produce the anti-a1HP ab. Furthermore, we also showed that the reactivity of against a monoclonal IgA1 was increased as carbohydrates were removed from the IgA1 hinge region. a rabbit polyclonal anti-sa1HP ab against serum IgA
